Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 12/20 | 0.68 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 2/20 | 0.59 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7633057 | 0.94 | KCNA3 (0.69) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL95124 | 0.93 | KCNA3 (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL1534891 | 0.93 | KCNA3 (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL8778496 | 0.93 | KCNA3 (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL68267 | 0.90 | HTR1B (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL9770352 | 0.88 | KCNA3 (0.81) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL2177350 | 0.88 | HTR1B (0.78) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902840 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902853 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902852 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | claimed |
| US-5362902-A | Diuretics and treatment of cardiovascular disorders | PFIZER INC. (US) | 1994-11-08 | — | — | US | claimed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| CN-101248049-B | Imidazole based lxr modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-5719155-A | CARDIOVASCULAR DISORDERS | JAPAN TOBACCO INC. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0733364-A1 | MEDICINAL COMPOSITION FOR CIRCULATORY ORGAN | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | disclosed |
| EP-0677519-A1 | CHROMAN DERIVATIVE AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5447900-A | Fluoran leuco dye and developer | RICOH COMPANY, LTD. (JP) | 1995-09-05 | — | — | US | disclosed |
| EP-0601184-A1 | FUSED PYRIDAZINE COMPOUND AND PHARMACEUTICAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5292750-A | piperidine compounds | NIPPON SHINYAKU CO. LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5192772-A | Administering moranoline derivatives; anticoagulants | NIPPON SHINYAKU CO. LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0319986-A2 | Fibrinolytic agents | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | HTR1B 1138/4885KCNA3 3029/4885SLC6A4 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.